Summary
Eli Lilly and Company (LLY) has filed a Current Report on Form 8-K dated February 6, 2025, to announce its financial results for the quarter and year ended December 31, 2024. While the 8-K itself does not contain the detailed financial figures, it explicitly incorporates by reference Exhibit 99.1, which is a press release detailing these results. Investors should refer to this press release for comprehensive information on the company's performance, including key financial metrics, revenue drivers, and potential forward-looking statements. The filing indicates that the information provided is being furnished and not deemed "filed" for certain regulatory purposes. This is standard practice for earnings releases. The primary takeaway for investors is to access the attached press release (Exhibit 99.1) to understand the company's recent financial health and outlook as presented by management.
Key Highlights
- 18-K filed on February 6, 2025, announcing financial results for the period ending December 31, 2024.
- 2Key financial and operational results are detailed in Exhibit 99.1, a press release dated February 6, 2025.
- 3Exhibit 99.1 is incorporated by reference into the 8-K filing, serving as the primary source of detailed financial information.
- 4The filing confirms the company's adherence to standard SEC reporting procedures for earnings announcements.
- 5Investors are directed to the press release for comprehensive details on revenue, profitability, and other performance indicators.
- 6No new material financial statements are presented directly within the 8-K; they are contained in the referenced press release.